Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, China Isotope & Radiation's PEG is 1. China Isotope & Radiation's 5-Year TTM EBITDA Growth Rate is 8.75.
China Isotope & Radiation's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was €0.13. Therefore, the Peter Lynch Fair Value for today is €1.16.
The historical rank and industry rank for China Isotope & Radiation's Peter Lynch Fair Value or its related term are showing as below:
FRA:5IR'
s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.81 Med: 1.78 Max: 3.4
Current: 1.86
During the past 11 years, the highest Price to Peter Lynch Fair Value Ratio of China Isotope & Radiation was 3.40. The lowest was 0.81. And the median was 1.78.
FRA:5IR's Price-to-Peter-Lynch-Fair-Value is ranked worse than 65.99% of 147
companies
in the Medical Devices & Instruments industry
Industry Median: 1.37
vs FRA:5IR: 1.86
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
China Isotope & Radiation (FRA:5IR) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 8.75 instead of 15 in this case.
China Isotope & Radiation's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
1.77
/
1.16
=
1.52
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Isotope & Radiation Peter Lynch Fair Value Related Terms
China Isotope & Radiation Peter Lynch Fair Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Isotope & Radiation Peter Lynch Fair Value Chart
FRA:5IR vs ABT, SYK, MDT: Peter Lynch Fair Value Comparison
For the Medical Devices subindustry, China Isotope & Radiation's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Isotope & Radiation Price-to-Peter-Lynch-Fair-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, China Isotope & Radiation's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where China Isotope & Radiation's Price-to-Peter-Lynch-Fair-Value falls into.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. China Isotope & Radiation's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was €0.13.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
China Isotope & Radiation (FRA:5IR) has a Peter Lynch Fair Value of €1.16 as of Aug. 28, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on China Isotope & Radiation and its competitors. According to the industry distribution chart, China Isotope & Radiation ranks #97 out of 147 companies in the Medical Devices & Instruments industry, placing it in the top 66%.
Is China Isotope & Radiation's Peter Lynch Fair Value too high?
China Isotope & Radiation's current Peter Lynch Fair Value is €1.16. Based on the distribution chart, China Isotope & Radiation ranks #97 out of 147 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, China Isotope & Radiation has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does China Isotope & Radiation's Peter Lynch Fair Value compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, China Isotope & Radiation ranks #97 out of 147 companies for Peter Lynch Fair Value. This places China Isotope & Radiation in the lower half of its industry. The industry median Peter Lynch Fair Value is 1.37. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Medical Devices & Instruments company?
The median Peter Lynch Fair Value among Medical Devices & Instruments companies is 1.37, based on 147 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on China Isotope & Radiation and its competitors. For the Medical Devices & Instruments industry, the median Peter Lynch Fair Value is 1.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Isotope & Radiation's current Peter Lynch Fair Value is €1.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Isotope & Radiation stock overvalued right now?
China Isotope & Radiation (FRA:5IR) has a current Peter Lynch Fair Value of €1.16. The stock's GF Value™ is €1.63, compared to a current price of €1.77 — trading 8.6% above its estimated fair value. The current Peter Lynch Fair Value is €1.16. China Isotope & Radiation's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For China Isotope & Radiation (FRA:5IR), the current Peter Lynch Fair Value is €1.16 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Isotope & Radiation (FRA:5IR) Overvalued in 2026?
Based on GuruFocus' analysis, China Isotope & Radiation stock appears to be overvalued.
The current stock price of €1.77 is trading 8.6% above its estimated GF Value™ of €1.63.
Key valuation signals for FRA:5IR:
Peter Lynch Fair Value: €1.16
GF Value™: €1.63 vs. price of €1.77 (8.6% above fair value)
No single metric tells the full story. See the FRA:5IR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Isotope & Radiation Corp is a Chinese company. It has five operating segments: (1) nuclear medicine; (2) radioactive source products; (3) irradiation; (4) nuclear medical equipment and related services; and (5) other businesses. Nuclear medicines: manufacturing and sale of a range of imaging diagnostic and therapeutic radio pharmaceuticals imaging, UBT diagnostic kits and test analysers and other products. Its radioactive source products segment involves the sale of medical and industrial radioactive source products and technical services. The company's operations are carried out and a majority of its customers are located in the PRC.
92GF Score
Get the complete analysis for FRA:5IR
Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5IR has been successfully added to your 
